Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Future JAK inhibitor combination approaches in myelofibrosis

Andrew Kuykendall • 25 Aug 2020
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Lenalidomide Luspatercept Navitoclax Pelabresib Pevonedistat Ruxolitinib Thalidomide

Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, outlines JAK inhibitor based combination therapies being investigated for myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Kuykendall

Practice-changing findings in MPNs from ASCO 2025 0:57
Practice-changing findings in MPNs from ASCO 2025
Andrew Kuykendall • 1 Jun 2025
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis 0:58
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis
Andrew Kuykendall • 1 Jun 2025
An overview of novel JAKis in myelofibrosis: which patients benefit from pacritinib & momelotinib? 1:31
An overview of novel JAKis in myelofibrosis: which patients benefit from pacritinib & momelotinib?
Andrew Kuykendall • 1 Jun 2025
Results from the VERIFY trial: the encouraging efficacy of rusfertide in patients with PV 2:32
Results from the VERIFY trial: the encouraging efficacy of rusfertide in patients with PV
Andrew Kuykendall • 1 Jun 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals